Biological characterization and clinical value of PLOD gene family in clear cell renal cell carcinoma

Author:

Shang Xuan1,Liu Liu2,Yan Min2,Ren Rui-Min3,Guo Ke-Xin2,Wang Jie2,Zhang Wei1,Chang Jia-Song2,Li Jia-Lei2,Gao Li-Juan1,Cao Ji-Min1

Affiliation:

1. The First Hospital, Shanxi Medical University

2. Shanxi Medical University

3. Shanxi Bethune Hospital (Third Hospital of Shanxi Medical University)

Abstract

Abstract

Background Studies have identified that procollagen-lysine, 2-oxoglutarate 5-dioxygenase (PLOD) gene family is closely related to tumor progression and metastasis in various cancers. However, the expression pattern, clinical value and function of PLOD gene family in clear cell renal cell carcinoma (ccRCC) have not yet been studied. Methods We investigated the expression, prognostic value, immune cell infiltration, genetic mutation, cell migration, and biological function of the PLOD gene family in ccRCC through comprehensive bioinformatic analysis and experimental validation, and predicted potential chemicals which regulate the expression of PLOD gene family using comparative toxicogenomics database (CTD) and docking analysis. Results The mRNA and protein expressions of PLOD gene family were highly increased in ccRCC tissues compared with normal tissues, and high expressions of all the three PLOD genes were positively related to every clinicopathological stages, poor overall survival (OS) and disease-free survival (DFS) in ccRCC patients. Fifty co-expressed genes of PLODs were found related with ccRCC. Functional enrichment analysis revealed that collagen synthesis, ECM-receptor interaction and lysine degradation were key biological functions of PLODs in ccRCC. A variety of chemicals were predicted to regulate the expression of PLOD gene family especially acetaminophen. Conclusion High expression of PLOD gene family is closely related to poor prognosis of ccRCC and they can predict any stage of ccRCC. PLOD gene family may serve as a prognostic biomarker and even a therapeutic target for ccRCC.

Publisher

Springer Science and Business Media LLC

Reference61 articles.

1. Cancer statistics, 2019;Siegel RL;Cancer J Clin,2019

2. Cancer statistics, 2020;Siegel RL;Cancer J Clin,2020

3. Nabi S, Kessler ER, Bernard B, Flaig TW, Lam ET. Renal cell carcinoma: a review of biology and pathophysiology. F1000Research 2018, 7:307.

4. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions;Lalani A-KA;Eur Urol,2019

5. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?;Sonpavde G;Eur Urol,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3